Breakthrough technologies to deliver safer and more effective treatments to patients


Molecular targets of neurodegenerative diseases are well identified and drugs able to clear those targets in vitro have been developed. However, in vivo, drugs do not pass through the Blood-Brain Barrier to get to the Central Nervous System.

We have taken up the challenge of brain drug delivery and we are developing new strategies to make drugs available where they are needed (targeted delivery).


Our solutions rely on proprietary nano-enabled drug delivery systems based on  implantable devices able to deliver drugs to the CNS continuously. After minimally-invasive surgery to get the device implanted, percutaneous access allows easy dosing for long term delivery of drugs with superior effectiveness and safety to conventional routes of administration.


Our products are platforms based on advanced medical devices that are intended to be used in combination with pharma compounds. 

Our nanotechnology-driven intrathecal implants maximize the effectiveness of therapies while reducing drug-derived side effects to zero.

Medtech pipeline

The core of our solutions are implantable devices acting on the CSF . We are in the CSF management and in the controlled delivery of drugs medtech sectors.

We have developed miniaturized prototypes for sustained delivery that have been successfully tested in rodents. Now we are developing prototypes for humans that we will test in large animals before we address clinical experimentation.

Pharmaceutical pipeline

Our pharma products are immunotherapies and hemoderivatives. We have ongoing discovery and validation programs for new or repurposed compounts in collaboration with academy and industry.

NIT001: our first pharmaceutical product is an anti-abeta drug specifically designed to target soluble abeta as a preventive treatment for Alzheimer’s disease. This is a proprietary drug fully owned by Neurostech.